Approaching treatment for immunological rejection of living-donor liver transplantation in rats

Yanhu Feng1†, Zhijian Han2†, Zedong Feng3†, Bofang Wang3†, Huijuan Cheng2, Luxi Yang2, Yangbing2, Baohong Gu3, Xuemei Li3, Yahao Li4, Yumin Li24*, Chen Wang5* and Hao Chen24*

Abstract

Background: The anti-immunological rejection therapy for small-for-size syndrome (SFSS) after live donor liver transplantation (LDLT) play a central role in keeping graft survival. The hepatocyte number and grafts function has undergone real-time changes with the proliferation and apoptosis of the grafts after reperfusion. Lacking an accurate and effective treatment regimens or indicators to guide the use of immunosuppressive drugs in SFS liver transplantation has made immunotherapy after SFS liver transplantation an urgent problem to be solved. Herein, we established small-for-size (SFS) and normal size liver transplantation model in rats to explore the effective indicators in guiding immunotherapy, to find an effective way for overcoming SFSS.

Methods: Lewis rats (donors) and BN rats (recipients) were used to mimic allograft liver transplantation and treated with tacrolimus. Local graft immune response was analyzed through haematoxylin and eosin and immunohistochemistry. Flow cytometry was used to assess the overall immune status of recipient. The pharmacokinetics mechanism of immunosuppressive drugs was explored through detecting CYP3A2 expression at mRNA level and protein levels.

Results: The results showed the local immune reaction of SFS grafts and systemic immune responses of recipient were significantly increased compared with those in normal size grafts and their recipient at four days after liver transplantation. Regression equation was used to regulate the tacrolimus dose which not only controlled tacrolimus serum concentration effectively but alleviated liver damage and improved survival rate.

Conclusions: This study showed that AST level and tacrolimus serum concentrations are effective indicators in guiding immunotherapy. Regression equation (T D = −0.494T C−0.0035AST+260.487) based on AST and tacrolimus serum concentration can be used as a reference for adjustment of immunotherapy after SFS liver transplantation, which is applicable in clinical practice.

Keywords: Living donor liver transplantation, Small-for-size syndrome, Tacrolimus, Immunotherapy
Background
Living donor liver transplantation (LDLT) has been used as a novel surgical technique for patients with end-stage liver disease since the first successful report in 1990 [1]. Split liver transplantation, LDLT and donation after circulatory death enlarged the organ pool for liver transplantation effectively [2]. These techniques are becoming the options used in therapy from infants to adults to address the shortage of donor organs [3–6]. However, small liver volume is unable to meet the adequate metabolic, synthetic and stably hemodynamic demands of the recipients. The postoperative allograft dysfunction, liver failure and potential severe morbidity or death have been termed as small-for-size syndrome (SFSS) [7]. Studies have shown that recipients also produce stronger immune rejection in the case of small-for-size (SFS) grafts when compared with normal volume liver grafts [8]. Recipients usually require an intensive immunosuppressive regimen, such as tacrolimus, to counter the enhanced rejection. However, severe organ damage and increased side effects (nephrotoxicity, hypertension and neurotoxicity) appeared in a dose-dependent manner [9]. What are the potential mechanisms for the change of tacrolimus metabolic dynamics in SFS liver transplantation? There is no effective and reliable treatment modality for immune rejection after SFS transplantation so far [10]. Graft volume and recipient standard liver volume ratio (GV/SLV) can be used as selection criteria, but it only reflects the amount of residual liver cells and it is not representative of the liver function. So, GV/SLV has to be assessed together with other factors, such as donor age, severity of the portal hypertension and the Model for End-Stage Liver Disease score of the recipient [11, 12]. Theoretically, the cell number and grafts function has undergone real-time changes with the proliferation and apoptosis of the grafts after reperfusion. Lacking an accurate and effective treatment regiments or indicators to guide the use of immunosuppressive drugs in SFS liver transplantation has made immunotherapy after SFS liver transplantation an urgent problem to be solved. We herein demonstrated the immune rejection change of SFS allograft in rats and explored the drug metabolic characteristic of tacrolimus in vivo in order to develop reliable guidance for immune rejection treatment after SFS transplantation.

Methods
Animals and ethics
The protocol of animal experiments was approved by the animal management committee of Lanzhou University Second Hospital and performed strictly according to the guideline on animal experimentation. Adult male Lewis rats and Brown Norway (BN) rats were purchased from Vital River, Beijing with weight 250-260 g and feeding in the standard SPF environment. Lewis rats were used as donors and BN rats as recipients. This method was also used in previous studies to establish allograft immunological rejection in rat liver transplantation model [13].

Study design
The rat orthotopic liver transplantation model was established based on Kamada’s technique [14]. The Man K technique was implemented for hepatolobectomy to obtain small volume of liver graft in rats [15]. The middle lobe of the donor rat was left untouched, while the other lobe underwent resection and resection to prepare for transplantation. In the control group, the normal whole liver was used as donor, and the weight of the liver in SFS group was about 40% of the recipient liver (range from 35 to 42%). After abdominal aortic fenestration, the liver is slowly perfused with warm singlet’s balanced solution. The portal vein is then transected and the liver taken out. The isolated graft is put in a container filled with ice-cold saline for further preparation. The prosthetic casing is then sheathed outside the portal vein and the infra hepatic vena cava. Portal vein and the infra hepatic vena cava are everted and fixed on the casing. All of the steps were under the good control, no complication was found. Finally, the small size or whole size orthotopic graft is transplanted into the recipient rat. After completion of the surgical procedure, recipient animals were recovered according to an intensive post-operative protocol. The warm ischemia time was 4 ± 1.6 min, the cold ischemia time was 31 ± 2.7 min.

Animals were divided into seven groups: (1) group of whole liver isograft (WI): BN rats as donors and recipients, n = 7; (2) group of small-for-size isograft (SI): BN rats as donors and recipients, n = 7; (3) group of whole liver allograft (WA): Lewis rats as donors and BN rats as recipients, n = 7; (4) group of small-for-size allograft (SA): Lewis rats as donors and BN rats as recipients, n = 7; (5) group of whole allograft tacrolimus treatment (WAT): Lewis rats as donors and BN rats as recipients, n = 7 (TAC99–25, Tecoland, USA, 1 mg/Kg, intramuscular injection); (6) group of small-for-size allograft tacrolimus treatment (SAT): Lewis rats as donors and BN rats as recipients, n = 7 (TAC99–25, Tecoland, USA). Dosages were adjusted according to the tacrolimus concentration and AST level and given as an intramuscular injection.

The survival of recipient rats was not recorded until death from rejection. In order to obtain the solid and liquid samples, additional three recipient rats of each
group were “sacrifice” after reperfusion at different time point. The rats were euthanized by IP injection of Eutha- 
nyl Forte (dosage:100 mg/kg, Virbac AH Inc., TX, USA).

Blood samples were taken before the “sacrifice” of the rats and the samples were sent to detect liver function. 
After the “sacrifice” of the rats, samples were collected 
including liver, kidney, lung, heart, and stomach. The 
specimens were also collected if the animal died. The death of the recipient was confirmed by histopathology.

**Tissue processing for haematoxylin and eosin (HE) stain**
All liver specimens were fixed by immersion for at least 
one day in 10% buffered formaldehyde phosphate. The 
tissues were subsequently dehydrated and embedded in 
paraffin wax to cut sections and performed HE staining 
as routine procedure.

**Immunohistochemistry (IHC)**
Immunohistochemical staining was performed using a 
HRP/DAB Detection IHC kit (Abcam, Cambridge, MA, 
USA) and counterstained with haematoxylin. The pri-
mary antibody was αβ TCR (1:200 mouse monopoly anti-
body, Santa Cruz Biotechnology Inc., American) and 
PCNA (1:250 mouse monopoly antibody, Santa Cruz 
Biotechnology Inc., America). The results were analyzed 
by liver cell counting (100 cells per fields for 10 fields 
were counted for each section, namely about 1000 hepa-
tocytes were counted) and calculating the percentage of 
αβ TCR and PCNA positive cells.

**TUNEL (terminal Deoxynucleotidyl Transferase mediated 
Nick-end labeling)**
Nucleus was counterstained with haematoxylin, mounted 
with neutral gum and viewed under the microscope. Im-
ages shown are representative of at least three inde-
pendent experiments which gave similar results. The results 
were analyzed by liver cell counting as PCNA staining.

**Liver function test**
The specimens were sent to the second Affiliated Hospital 
of Lanzhou University where liver function was detected 
through an automatic biochemical analyzer.

**Western blot**
Western blot was performed with general procedure and 
Gelworks 1D software (UVP, Inc.) was used to analyze 
the protein expression intensity and calculate the pro-
portion of CYP3A2 protein intensity with β-actin protein 
intensity in the same samples (CYP3A2 antibodies:1:1000 
Abcam, catalog number ab195627; β-actin 1:2500, Proto-
imTech, catalog number 60008–1-Ig). The result was 
recorded as mean ± SD.

**Statistical analysis**
All data are presented as means±SD. Statistical analysis 
was performed by the t test and Kruskal-Wallis test 
using SPSS19.0 software. Survival rates were assessed by 
the Kaplan-Meier method. The log-rank test was used to 
compare significance. Chi-square test analyzed the posi-
tive expression ratio of αβ TCR positive staining cells. 
The CD4+ CD25+ positive cells percentage, liver func-
tion, serum blood indexes, IL-17 and CYP3A2 expres-
sion levels and tacrolimus serum concentration were 
analyzed by Student’s t-test or Kruskal-Wallis test. 
Mann-Whitney test and logistical regression analysis were 
used for correlation analysis. P<0.05 was considered 
statistically significant.

**Results**

**Survival analysis**
All recipients of SFS allograft group, the group without 
immune rejection therapy, died within nine days. Their 
average survival time was 6.29 days which was lower 
than the WAT group which survived an average of 8.29 
days (P = 0.027). The use of Tacrolimus significantly 
prolonged the survival time of the WAT and the SAT 
groups whose survival time were 57.43 days and 28.00 
days respectively, significantly higher than the untreated 
group (p < 0.01). The survival time of the SAT group 
was lower than the WAT group although they received 
the same tacrolimus treatment (p = 0.047). Compared 
with the SAT group, the mean survival time for the SATa 
group was significantly prolonged by adjusting the

![Survival analysis. Tacrolimus remarkably prolonged both WAT 
and SAT group survivals (p = 0.047, compared with WA and SA), 
but there was still significant difference between WAT and SAT p = 0.047). 
Compared to the SAT group, mean survival time was much 
longer than that in SATa group (p = 0.031). 28-day cumulative 
 survival rates (85.7%) of WAT group were higher than SAT group 
(28.6%) (P = 0.019, log-rank test). The survival rate (51.7%) of SAa 
is higher than SAT group (P = 0.266, log-rank test), whole size allografts 
(WA), small-for-size allograft (SA), whole size allografts+Tac (WAT), 
small-for-size allograft+Tac (SAT), small-for-size allograft+Tac altered 
dose (SATa)
amount of tacrolimus under the guidance of a regression equation based on tacrolimus blood concentration and AST serum values (39.71 ± 28.99, \( p = 0.331 \)). The 28 days cumulative survival rate of WAT group was 85.7% which was significantly higher than the SAT group of 28.6% (\( P = 0.019 \), log-rank test). The SATa group’s cumulative survival rate was 51.7% which also higher than the SAT group. But there was no statistical difference (\( P = 0.266 \), log-rank test) (Fig. 1 and Table 1).

### Histological features in liver graft, lungs and kidneys

The whole size liver isograft was normal at four days after reperfusion. The SFS isograft showed morphological changes with moderate red blood cells accumulation in sinus cavity. Large amounts of cell infiltration and some liver structures destruction was present in both whole size and SFS allograft rats. Acute rejection was found in SFS allograft rats including portal area inflammatory cell infiltration, hepatic sinusoidal endothelial cells inflammatory changes, bile duct necrosis and hepatic sinusoid cells infiltration (Fig. 2). The pathological damage to lungs and kidneys was more obvious in the SAT group four days after surgery including pulmonary interstitial edema, lymphocyte infiltration, erythrocyte exudation, alveolar wall

| Group | Number | Survival days | Mean + SD |
|-------|--------|---------------|-----------|
| WA    | 7      | 7, 7, 8, 8, 9, 11 | 8.29 ± 1.38 |
| SA    | 7      | 4, 5, 6, 6, 7, 7, 9 | 6.29 ± 1.54 |
| WAT   | 7      | 25, 30, 45, 60, 63, 89, > 90 | 57.43 ± 24.97 |
| SAT   | 7      | 5, 9, 12, 15, 20, 45, > 90 | 28.00 ± 29.12 |
| SATa  | 7      | 8, 12, 23, 29, 51, 65, > 90 | 39.71 ± 28.99 |

>90 was taken as 90 on statistic analysis

---

**Fig. 2** Histology of liver grafts and other organs at four days after transplantation. HE staining magnification x 120, whole size allografts+Tac (WAT), small-for-size allograft+Tac (SAT), small-for-size allograft+Tac altered dose (SATa). Whole size isograft (WI), small-for-size isograft (SI), whole size allograft (WA), small-for-size allograft (SA)
thickening, progressive glomerular swelling and diffuse nephrolithia ball-like bleeding. All of the above-mentioned organ pathological lesions were significantly reduced or did not occur in the SATa Group (Fig. 2).

**Infiltrating lymphocytes phenotypic of liver graft and detection of hepatocyte proliferation and apoptosis**

Immunohistochemical analysis showed that the αβ TCR positive lymphocytes in allografts were significantly higher than that of the isografts at four days after transplantation. Similarly, the αβ TCR positive expression cell number in SFS allografts was significantly higher than that in whole size allografts ($p < 0.05$, Fig. 3).

Compared with the WAT group, the proportions of PCNA positive expression and TUNEL positive staining were significantly increased in the SAT and the SATa group ($P < 0.01$). The hepatocytes proliferation was significantly increased in the SATa group compared with the SAT group ($p < 0.05$). On the contrary, the number of apoptotic cells was significantly decreased ($p < 0.05$) (Fig. 3).

**Phenotypic analysis of peripheral blood lymphocytes in recipients**

Flow cytometry showed that CD4+CD25+ lymphocytes were significantly less in peripheral blood of allografts than isografts four days after transplantation. Similarly, the positive expression rates of CD4+CD25+ lymphocytes in SFS allografts was significantly lower than those in whole size allografts ($p < 0.01$, Fig. 4).

**Expression of cytokine IL-17 and CYP3A2**

IL-17 was hardly expressed in isografts four days after the operation. The expression of IL-17 was increased by...
three times in whole size allografts and five times in SFS allografts in comparison with the corresponding isografts ($P < 0.01$). Its expression in SFS allograft was also significantly higher than that in whole size allografts ($P < 0.05$, Fig. 5).

The expression of CYP3A2 decreased significantly in the early postoperative period for SFS liver grafts. Compared with the normal size whole liver transplantation group, the expression of CYP3A2 in SFS grafts decreased by about 60% at 12 h, 50% for 24 h and 30% for 48 h after transplantation. However, the expression of CYP3A2 gradually recovered at 96 h after transplantation (Fig. 5).

**Tacrolimus blood concentration analysis**

The blood concentration of tacrolimus was significantly higher in the SFS transplantation with tacrolimus routine treatment group than the whole size transplantation group at different time points ($p < 0.05$). The peak concentration of tacrolimus in the SFS group was more than two times higher than the whole size transplantation group. However, the tacrolimus blood concentration was relatively stable in SFS group after adjusting the dosage of tacrolimus under the guidance of the regression equation based on tacrolimus blood concentration and AST level. Moreover, the serum concentration of tacrolimus
was significantly lower in the SFS group using altered dose on the basis of Tc and AST (SATa) than that of the unadjusted SFS group (SAT) \((P < 0.05, \text{Fig. 6})\).

Liver function analysis

Compared with the WAT group, AST concentration were significantly higher in SAT group and SATa group 48 h after operation \((P < 0.01)\). The AST concentration of the SATa group was lower than the SAT group although there was no significant difference statistically between SAT group and SATa group. The trend of total bilirubin was similar to AST (Fig. 6).

Correlation analysis

The changes in serum concentration of tacrolimus and the corresponding values of RCA (ratio of CYP3A4 to actin), RPA (ratio of proliferation to apoptosis) and AST are listed in Table 2. Correlation analysis showed a significant correlation between RCA, RPA, and AST (RCA and RPA \(R = 0.976 \ P = 0.001; \) RPA and AST \(R = -0.962 \ P = 0.001; \) RCA and AST \(R = -0.906 \ P = 0.005\)). The serum concentration of tacrolimus decreased with the
The Logistical regression equation was $TD = -0.494TC - 0.0035AST + 260.487$ (Fig. 7).

**Discussion**

SFS liver transplantation as an effective means of expanding the donor liver has been recognized worldwide. Although the successful implementation of surgical techniques has resulted in a significant reduction in the mortality rate of patients waiting for liver transplantations, the surgery itself inevitably leads to new compelling problems related to the difficulty in immunotherapy after SFS liver transplantation.

Although the optimal size of grafts for SFS liver transplantation remains the focus of controversy, it is generally assumed that the graft-to-recipient weight ratio should exceed 0.8% and GV/SLV should exceed 35–40%. According to the Fan [16] and Kawasaki [17] proposed guidelines, the volume fraction of small grafts was chosen 40% (35–42%) in our study. In order to explore whether recipients drive different degrees of rejection as the graft volume changes, animal models of the whole liver volume and SFS allograft and isograft were established and the rejection between them were compared. The results showed that acute rejection was more pronounced in SFS grafts (Fig. 2). A large number of

![Fig. 7](image-url)
inflammatory cells infiltrated into hepatic sinus and around the portal area. These infiltrating inflammatory cells were dominated by αβTCR positive phenotypes, which indicated that the infiltrating cells were mature lymphocytes. αβTCR plays an important role in antigen presentation. Expression of αβTCR on lymphocytes contributes to the enhancement of immune responses (Fig. 3). In addition to the enhanced local immune response, the systemic immune response was also significantly strengthened in SFS transplant recipients, and the number of CD4+CD25+ T lymphocytes in peripheral blood was decreased significantly (Fig. 4) while the expression level of IL-17 increased significantly (Fig. 5).

CD4+CD25+ T cells can inhibit the activation, proliferation, and function of T lymphocytes [18]. CD4+CD25+ T cells also inhibited allograft T lymphocyte responses. For example, it suppresses allograft rejection of the skin and solid organs [19–21]. Studies have shown that CD4+CD25+ T cells play a key role in immune tolerance models [22, 23]. Recent studies found IL-17 levels were increased in acute rejection of animal models or patients after early transplantation of the kidneys, lungs and heart [24–26]. In our study, the elevated expression of IL-17 was observed in an acute rejection model of SFS liver transplantation in rats. The above evidence suggests that the recipient has enhanced immune rejection of SFS allografts. This is consistent with the Takashi Omura study [27].

Tacrolimus is metabolized predominantly in the liver as most of the immunosuppressive drugs. However, the number of hepatocytes reduced due to the SFS surgery and liver function was impaired after ischemia-reperfusion, therefore, the metabolic capacity of hepatocytes was inevitably affected to some extent. As a result, the plasma concentration of tacrolimus was likely to increase in the case of reduced hepatic metabolism in SFS liver grafts. To prove the hypothesis, the plasma concentration of tacrolimus was measured at different time points after the whole size and SFS liver transplantation (Fig. 6). High concentrations of tacrolimus not only aggravated liver metabolic burden, but also caused other organ damage as well as unpredictable side effects. In the early stage of transplantation, the concentrations of AST and total bilirubin in the SFS recipients were increased significantly compared with the normal size liver transplant recipients, and the number of apoptotic cells was also increased significantly (Fig. 6). Organs damage would inevitably affect the survival rate of grafts and recipients. Although tacrolimus can significantly prolong the survival in the normal size and SFS recipients compared with the subjects without using tacrolimus ($p < 0.01$), the average survival time of the SFS graft was significantly lower than that of the normal size liver graft ($p = 0.047$).

The mechanism under the change in tacrolimus blood concentration was explored to find an effective way to accurately guide tacrolimus use for SFS graft recipients. Cytochrome P450 3A enzymes play a central role in the metabolism of almost 50% of the currently used drugs including tacrolimus [28]. In particular, Ca-neurocyclin inhibitors are mainly metabolized by the CYP3A4 enzyme, which is a metabolic enzyme in the liver. The CYP3A4 enzyme in the human liver is equivalent to the CYP3A2 enzyme in the rat liver [29, 30]. In our previous study, we showed that cytochrome oxidase CYP3A and drug efflux pump P-gp were two major influencing factors in drug metabolism. The polymorphisms of P-gp and CYP3A were found to be closely correlated to tacrolimus plasma concentrations among different individuals [31]. Our current study found that the expression of CYP3A2 was significantly reduced in the early stages of SFS grafts. The results were similar to those of Powis and his colleagues who found that the content and activity of CYP3A4 rapidly decreased after partial resection of human liver [32]. However, molecular mechanism how the graft volume change affecting the CYP3A2 will be further elucidated in subsequent studies. We have already discovered that nitric oxide signaling pathways potentially play an important role in this mechanism.

The ratio of hepatocyte proliferation and apoptosis (RPA) significantly increased when the CYP3A2 level gradually recovered 72 h after transplantation ($p < 0.01$). Correlation analysis was performed in order to find the relationship between CYP3A2, RPA and AST. RPA represents the SFS liver graft regeneration capacity, which increases with hepatocytes proliferation and decrease of apoptosis. After SFS liver transplantation, surviving small-volume grafts tend to proliferate to the original liver volume. Drug metabolism capacity was also enhanced as hepatocytes number increased and the liver function was restored. As shown in this study, CYP3A2 increased as RPA increases. AST decreased with the recovery of liver function which was consistent with the results. RPA was negatively correlated with AST.

Many attempts have been made to find a method for the treatment of immune rejection after SFS liver transplantation. Kishino and his colleagues showed that the CYP3A4 difference between individuals was caused by graft volume and recipient liver standard volume ratio and the recipient age [33]. In addition, Fukatsu et al. reported that there was a significant correlation between the weight of the graft and the clearance of tacrolimus in patients receiving liver transplantation [34]. Sugarawa’s study indicated that there was a correlation between the optimal dose of tacrolimus and GV/SLV. The dose of tacrolimus early after SFS liver transplantation could be estimated by using the equation established by the GV/SLV [35].
Conclusions

In summary, a regression equation was established based on logistic regression analysis of tacrolimus plasma concentration and AST (\( T_{D} = 0.494 T_{C} - 0.0035 A ST + 260.487 \)). The dose of tacrolimus was adjusted based on this equation in the early postoperative period in rats. More importantly, blood specimens are easier to obtain. Therefore, it is an effective and feasible method to adjust the dose of tacrolimus after SFS liver transplantation using our established regression equation. There are also shortcomings in this experiment. Although the tacrolimus is the main drug to anti-rejection in clinical practice, other drugs need to be tested in the future. Clinical trials are needed to further evaluate the value of this study in immunotherapy for SFS liver transplantation. CYP2C, which has a role closer to human CYP3A enzymes did not be measure, will be tested in ongoing study.

Abbreviations
AST: Aspartate aminotransferase; BN rats: Brown Norway rats; CYP3A2: Cytochrome P450 3A2; GV/SLV: Graft volume and recipient standard liver volume ratio; IHC: Immunohistochemistry; LDLT: Liver donor liver transplantation; PON1: Proliferating cell nuclear antigen; RCA: Ratio of CYP3A4 to actin; RPA: Ratio of proliferation to apoptosis; SFS: Small-for-size; SFSS: Small-for-size syndrome; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling

Acknowledgements
Not applicable.

Availability data and materials
The datasets used and the current study are available from the corresponding author on reasonable request.

Authors’ contributions
Z.J.H., Y.H.L., participated in writing of the paper. H.C., B.H.G. and X.M.L. contributed to the study design and animal transplantation. Z.J.H., Y.H.L. participated in writing of the paper. H.C., B.H.G. and X.M.L. contributed to the study design and animal transplantation. Z.J.H., Y.B.L., L.X.Y., Z.J.H., Y.H.L. participated in writing of the paper. H.C., B.H.G. and X.M.L. contributed to the study design and animal transplantation. Z.J.H., Y.B.L., L.X.Y., Z.J.H., Y.H.L. participated in writing of the paper. H.C., B.H.G. and X.M.L. contributed to the study design and animal transplantation. Z.J.H., Y.B.L., L.X.Y., Z.J.H., Y.H.L. participated in writing of the paper. H.C., B.H.G. and X.M.L. contributed to the study design and animal transplantation. Z.J.H., Y.B.L., L.X.Y., Z.J.H., Y.H.L. participated in writing of the paper.

Funding
This study was supported by National Natural Science Foundation of China (No. 81670594, 81470594, 81470791, 81376597 from Hao Chen and 31270532 from Weihua Wilde. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2015;22(11):1438–46.

Acknowledgements
Not applicable.

Availability data and materials
The datasets used and the current study are available from the corresponding author on reasonable request.

Authors’ contributions
Z.J.H., Y.H.L., participated in writing of the paper. H.C., B.H.G. and X.M.L. contributed to the study design and animal transplantation. Z.J.H., Y.B.L., L.X.Y., and Y.H.F. participated in the immunohistochemistry. H.C. and H.J.C. participated in data analysis. H.C. and Y.M.L. contributed to the design and discussion of the manuscript. Z.D.F., C.W., B.F.W. and H.C. participated in the article revision. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou 730030, China. 2. Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou 730030, China. 3. Medical School of Lanzhou University, Lanzhou 730030, China. 4. Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China. 5. Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China.

Received: 11 October 2018 Accepted: 27 November 2018 Published online: 13 January 2020

References
1. Strong RW, Lynch SV, Ong TH, Matsunami H, Yano T, Elderson GA. Successful liver transplantation from living donors to her son. N Engl J Med. 1990;322(21):1505–7.
2. Fisher RA. Living donor liver transplantation: is it worth the risk? Nat Rev Gastroenterol Hepatol. 2017;14(6):373–82.
3. Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical techniques and current challenges to expanding indication of patients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2015;15(11):37–58.
4. Dutkowski P, Schrecker B, DeOliveira ML, Multaupt B, Clavien PA. Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology. 2015;148(2):307–23.
5. Xu Y, Chen Y, Yin H, Wang H, Leng J, Dong J. Living donor liver transplantation using dual grafts: experience and lessons learned from cases in China. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2015;22(1):1438–46.
6. Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203–17.
7. Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2005;5(11):2605–10.
8. Yang ZF, Ho DW, Chu AC, Wang YQ, Fan ST. Linking inflammation to acute rejection in small-for-size liver allografts: the potential role of early macrophage activation. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2004;4(2):196–209.
9. Taber DJ, Dupuis RE, Fann AL, et al. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transpl. 2002;8(3):219–23.
10. Kishino S, Ohno K, Shimamura T, Furukawa H, Todo S. A nomogram for predicting the optimal oral dosage of tacrolimus in liver transplant recipients with small-for-size grafts. Clin Transpl. 2006;20(4):443–9.
11. Alim A, Erdogan Y, Yuzer T, Tokat Y, Oezcelik A. Graft-to-recipient weight ratio threshold adjusted to the model for end-stage liver disease score for living donor liver transplantation. Liver Transpl. 2016;22(12):1643–8.
12. Hill MJ, Hughes M, Jie T, et al. Graft weight/recipient weight ratio: how well does it predict outcome after partial liver transplants? Liver Transpl. 2009;15(9):1056–62.
13. Zimmermann FA, Davies HS, Knoll PP, Gokel JM, Schmidt T. Orthotopic liver allografts in the rat. The influence of strain combination on the fate of the graft. Transplantation. 1984;37(4):406–10.
14. Kamada N, Calne RY. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation. 1978;28(1):47–50.
15. Man K, Lo CM, Ng IO, et al. Liver transplantation in rats using small-for-size grafts: a study of hemodynamic and morphological changes. Arch Surg (Chicago, Ill). 1960;2001;136(3):290–5.
16. Fan ST, Lo CM, Liu CL, Young BH, Chan JK, Ng IO. Safety of donors in live donor liver transplantation using right lobe grafts. Arch Surg (Chicago, Ill). 1960;2000;135(3):336–40.
17. Kawasaki S, Makuuchi M, Matsumani H, et al. Living related liver transplantation in adults. Ann Surg. 1998;227(2):269–74.
18. Piccirillo CA, Shevach EM. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol. 2004;16(2):81–8.

19. Gregori S, Casorati M, Amuchastegui S, Smirolodo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol (Baltimore, Md). 1950;2001;167(4):3789–96.

20. Kingsley CI, Karim M, Bushell AR, Wood KL. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol (Baltimore, Md). 1950;2002;168(3):1080–6.

21. Lee MK, Moore DJ, Jarrett BP, et al. Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. J Immunol (Baltimore, Md). 1950;2004;172(11):6539–44.

22. Graca L, Le Moine A, Lin CT, Fairchild PJ, Cobbold SP, Waldmann H. Donor-specific transplantation tolerance: the paradoxical behavior of CD4+CD25+ T cells. J Immunol (Baltimore, Md : 1950). 2001;167(4):1945–53.

23. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol (Baltimore, Md : 1950). 2000;166(6):3789–96.

24. Li J, Zhou X, Gaowa S, et al. The critical role of induced CD4+ FoxP3+ regulatory cells in suppression of Interleukin-17 receptor-mediated cardiac allograft rejection in a rat model. Eur J Cardiothorac Surg. 2006;29(5):777–83.

25. Zhou W, Zhou X, Gaowa S, et al. The critical role of induced CD4+ FoxP3+ regulatory cells in suppression of Interleukin-17 production and attenuation of mouse Orthotopic lung allograft rejection. Transplantation. 2013;99(7):1356–64.

26. Chen A, Zhou X, Tang S, Liu M, Wang X. Evaluation of the inhibitory potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach. Sci Rep. 2016;6:28402.

27. Kishino S, Ogawa M, Takekuma Y, et al. The variability of liver graft function and urinary 6beta-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients. Clin Transpl. 2004(18)(2):124–9.

28. Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57(6–7):479–84.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.